Table 2. Analysis of the risk factors for clinical outcome.
| Univariate analysis | PFS | OS | Multivariate analysis | PFS | OS | ||
|---|---|---|---|---|---|---|---|
| P | P | HR (95% CI) | P | HR (95% CI) | P | ||
| CD58 mutation | 0.004 | 0.03 | COO (non –GCB) | 2.26 (1.22-4.18) | 0.009 | 3.15 (1.43-6.91) | 0.004 |
| TP53 mutation | 0.03 | 0.011 | B symptoms | 1.89 (1.07-3.35) | 0.029 | 2.36 (1.21-4.58) | 0.011 |
| Ann Arbor stage III/IV | 0.026 | 0.05 | CD58 mutation | 3.75 (1.63-8.63) | 0.002 | 3.97 (1.49-10.57) | 0.006 |
| COO (non-GCB) | 0.033 | 0.024 | TP53 mutation | 2.85 (1.40-5.82) | 0.004 | 4.84 (2.09-11.21) | < 0.001 |
| B symptoms | 0.019 | 0.04 | |||||
| MYC aberration | 0.016 | 0.158 | |||||
| BM involvement | 0.036 | 0.012 | |||||
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival